FibroBiologics Common Profitability Analysis
| FBLG Stock | 4.93 0.70 16.55% |
Net Loss | First Reported 2010-12-31 | Previous Quarter -16.5 M | Current Value -15.7 M | Quarterly Volatility 5.1 M |
For FibroBiologics Common profitability analysis, we use financial ratios and fundamental drivers that measure the ability of FibroBiologics Common to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well FibroBiologics Common Stock utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between FibroBiologics Common's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of FibroBiologics Common Stock over time as well as its relative position and ranking within its peers.
FibroBiologics |
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of FibroBiologics Common. If investors know FibroBiologics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about FibroBiologics Common listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of FibroBiologics Common is measured differently than its book value, which is the value of FibroBiologics that is recorded on the company's balance sheet. Investors also form their own opinion of FibroBiologics Common's value that differs from its market value or its book value, called intrinsic value, which is FibroBiologics Common's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because FibroBiologics Common's market value can be influenced by many factors that don't directly affect FibroBiologics Common's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between FibroBiologics Common's value and its price as these two are different measures arrived at by different means. Investors typically determine if FibroBiologics Common is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, FibroBiologics Common's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
FibroBiologics Common Total Debt vs. Net Income Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining FibroBiologics Common's current stock value. Our valuation model uses many indicators to compare FibroBiologics Common value to that of its competitors to determine the firm's financial worth. FibroBiologics Common Stock is one of the top stocks in net income category among its peers. It also is rated as one of the top companies in total debt category among its peers . At this time, FibroBiologics Common's Net Loss is most likely to decrease significantly in the upcoming years. Comparative valuation analysis is a catch-all technique that is used if you cannot value FibroBiologics Common by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.FibroBiologics Total Debt vs. Net Income
Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
FibroBiologics Common |
| = | (16.48 M) |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
FibroBiologics Common |
| = | 10.57 M |
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
FibroBiologics Total Debt vs Competition
FibroBiologics Common Stock is rated as one of the top companies in total debt category among its peers. Total debt of Biotechnology industry is currently estimated at about 440.08 Million. FibroBiologics Common holds roughly 10.57 Million in total debt claiming about 2.4% of stocks in Biotechnology industry.
FibroBiologics Common Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in FibroBiologics Common, profitability is also one of the essential criteria for including it into their portfolios because, without profit, FibroBiologics Common will eventually generate negative long term returns. The profitability progress is the general direction of FibroBiologics Common's change in net profit over the period of time. It can combine multiple indicators of FibroBiologics Common, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Net Interest Income | -147 K | -154.3 K | |
| Operating Income | -8.9 M | -8.4 M | |
| Net Loss | -16.5 M | -15.7 M | |
| Income Before Tax | -16.5 M | -15.7 M | |
| Net Loss | -16.5 M | -15.7 M | |
| Total Other Income Expense Net | -6.7 M | -7 M |
FibroBiologics Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on FibroBiologics Common. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of FibroBiologics Common position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the FibroBiologics Common's important profitability drivers and their relationship over time.
FibroBiologics Common Profitability Trends
FibroBiologics Common profitability trend refers to the progression of profit or loss within a business. An upward trend means that FibroBiologics Common's profit has generally increased over time, and a downward profitability trend means profits are declining. Recognizing problems early in profitability trends allows investors to address revenue and cost issues in advance. Investors and analysts usually monitor three types of profitability trends: gross, operating, and net. Gross profit is the difference between revenue and costs of goods sold. Operating profit is FibroBiologics Common's gross profit minus its overhead. After you account for other unusual revenue, expenses, and costs, you get net profit. Gross profit trends are often a good indicator of future profitability. If you have high gross profit margins, you have a better chance to cover overhead and make money.
FibroBiologics Common Profitability Drivers Correlations
One of the toughest challenges investors face today is learning how to quickly synthesize and read into endless financial statements and information provided by the company, SEC reporting, and various external parties. Understanding the correlation between FibroBiologics Common different financial indicators related to revenue and profit generation helps investors identify and prioritize their investing strategies towards FibroBiologics Common in a much-optimized way. Analyzing correlations between profit drivers that are directly associated with dollar figures is the most effective way to break down FibroBiologics Common's future profitability.
Click cells to compare fundamentals
Use FibroBiologics Common in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if FibroBiologics Common position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in FibroBiologics Common will appreciate offsetting losses from the drop in the long position's value.FibroBiologics Common Pair Trading
FibroBiologics Common Stock Pair Trading Analysis
The ability to find closely correlated positions to FibroBiologics Common could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace FibroBiologics Common when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back FibroBiologics Common - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling FibroBiologics Common Stock to buy it.
The correlation of FibroBiologics Common is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as FibroBiologics Common moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if FibroBiologics Common moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for FibroBiologics Common can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your FibroBiologics Common position
In addition to having FibroBiologics Common in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Penny Thematic Idea Now
Penny
Solid stocks, funds or ETFs with below average market capitalization and typicl daily price below 2. The Penny theme has 56 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Penny Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Information and Resources on Investing in FibroBiologics Stock
When determining whether FibroBiologics Common is a strong investment it is important to analyze FibroBiologics Common's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact FibroBiologics Common's future performance. For an informed investment choice regarding FibroBiologics Stock, refer to the following important reports:Check out Investing Opportunities. You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
To fully project FibroBiologics Common's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of FibroBiologics Common at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include FibroBiologics Common's income statement, its balance sheet, and the statement of cash flows.